Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596563 | 0.94 | DRD2 (0.40) | DRD2CYP3A4SLC6A2DRD3SLC22A2 | |
| SCHEMBL5405084 | 0.94 | DRD2 (0.37) | DRD2CYP3A4SLC6A2DRD3SLC22A2 | |
| SCHEMBL5419785 | 0.94 | DRD2 (0.39) | DRD2 | |
| SCHEMBL5597027 | 0.88 | CARM1 (0.40) | DRD2 | |
| SCHEMBL5410451 | 0.88 | CCR3 (0.39) | DRD2 | |
| SCHEMBL5419710 | 0.88 | CARM1 (0.40) | — | |
| SCHEMBL5420304 | 0.87 | DRD2 (0.39) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| SCHEMBL5415562 | 0.86 | DRD2 (0.40) | DRD2DRD3 | |
| SCHEMBL5421297 | 0.86 | DRD2 (0.40) | DRD2DRD3 | |
| SCHEMBL5410740 | 0.85 | NOS3 (0.37) | DRD2DRD3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160894-B2 | Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-01-09 | — | — | US | claimed |
| EP-1632492-A1 | TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2006-03-08 | — | — | EP | claimed |
| US-20050096310-A1 | Tricyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096310-A1 | Tricyclic compound | MYLK3, CSNK1A1L, MYLK | DRD2 2064/4885CYP3A4 2411/4885SLC6A2 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.